Showing results (1721-1730 of 1,769) with videos related to

Sort By:
Pageof 177
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2021
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human GliomasEdgar Gonzalez-Buendia, Junfei Zhao, Lu Wang, et al.
Plos One|December 7, 2013
PRICKLE1 interaction with SYNAPSIN I reveals a role in autism spectrum disordersLily Paemka, Vinit B Mahajan, Jessica M Skeie, et al.
Human Mutation|May 16, 2013
Mutations in extracellular matrix genes NID1 and LAMC1 cause autosomal dominant Dandy-Walker malformation and occipital cephalocelesBenjamin W Darbro, Vinit B Mahajan, Lokesh Gakhar, et al.
Gender Medicine|September 28, 2011
Optical technologies and molecular imaging for cervical neoplasia: a program project updateTimon P H Buys, Scott B Cantor, Martial Guillaud, et al.
Nature Communications|February 13, 2021
The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasmsJason R Schwartz, Jing Ma, Jennifer Kamens, et al.
Reviews in Fish Biology and Fisheries|June 26, 2023
Global responses to the COVID-19 pandemic by recreational anglers: considerations for developing more resilient and sustainable fisheriesJ Robert Britton, Adrian C Pinder, Josep Alós, et al.
Endoscopy|June 12, 2025
Clinical decision tree for optimising endoscopic assessment of signet ring cell carcinoma in hereditary diffuse gastric cancer surveillanceLianlian Wu, Judith Honing, Anjui Wu, et al.
International Journal of Cancer|September 11, 2010
Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia: Testing a device as an adjunct to colposcopyScott B Cantor, Jose-Miguel Yamal, Martial Guillaud, et al.
Nature Genetics|June 30, 2009
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancerMark M Pomerantz, Nasim Ahmadiyeh, Li Jia, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Pageof 177